Title:
MUTATED ANTIBODY-DEPENDENT INFECTION ENHANCING DOMAINS OF HIV
Document Type and Number:
WIPO Patent Application WO1998001570
Kind Code:
A3
Abstract:
HIV virus mutants having an alteration which inhibits induction of enhancing antibody to said virus are described. Also described are HIV virus mutants in which an antibody-dependent enhancing domain in gp41 includes amino acid alterations. Also described are HIV vaccines comprising HIV gp160 mutants in which an antibody-dependent enhancing domain in gp41 includes at least one amino acid alteration.
More Like This:
Inventors:
MITCHELL WILLIAM M (US)
Application Number:
PCT/US1997/011667
Publication Date:
February 26, 1998
Filing Date:
July 02, 1997
Export Citation:
Assignee:
UNIV VANDERBILT (US)
MITCHELL WILLIAM M (US)
MITCHELL WILLIAM M (US)
International Classes:
C07K14/16; C12N7/00; C12N15/59; A61K39/00; (IPC1-7): C12N15/59; C12N7/00; C07K14/16
Domestic Patent References:
| WO1995007987A2 | 1995-03-23 | |||
| WO1997014442A1 | 1997-04-24 |
Foreign References:
| US5019510A | 1991-05-28 |
Other References:
S.C. KLIKS ET AL.: "V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 90, December 1993 (1993-12-01), WASHINGTON US, pages 11518 - 11522, XP002049757
P. AUEWARAKUL ET AL.: "Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand", VIRAL IMMUNOLOGY, vol. 9, no. 3, March 1996 (1996-03-01), US, pages 175 - 185, XP002049758
S.B. JIANG ET AL: "Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp140/gp41", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 174, no. 6, 1 December 1991 (1991-12-01), NEW YORK US, pages 1557 - 1563, XP002049759
W.E. ROBINSON JR ET AL.: "Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro", JOURNAL OF VIROLOGY., vol. 64, no. 11, November 1990 (1990-11-01), BALTIMORE US, pages 5301 - 5305, XP002049760
J.R MASCOLA ET AL.: "Summary report: workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 9, no. 12, December 1993 (1993-12-01), NEW YORK US, pages 1175 - 1184, XP002049761
MITCHELL W M ET AL: "Induction of mucosal anti-HIV antibodies by facilitated transfection of airway epithelium with lipospermine/DNA complexes", IMMUNOTECHNOLOGY, vol. 1, no. 3, December 1995 (1995-12-01), AMSTERDAM NL, pages 211-219, XP004052723
P. AUEWARAKUL ET AL.: "Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand", VIRAL IMMUNOLOGY, vol. 9, no. 3, March 1996 (1996-03-01), US, pages 175 - 185, XP002049758
S.B. JIANG ET AL: "Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp140/gp41", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 174, no. 6, 1 December 1991 (1991-12-01), NEW YORK US, pages 1557 - 1563, XP002049759
W.E. ROBINSON JR ET AL.: "Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro", JOURNAL OF VIROLOGY., vol. 64, no. 11, November 1990 (1990-11-01), BALTIMORE US, pages 5301 - 5305, XP002049760
J.R MASCOLA ET AL.: "Summary report: workshop on the potential risks of antibody-dependent enhancement in human HIV vaccine trials", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 9, no. 12, December 1993 (1993-12-01), NEW YORK US, pages 1175 - 1184, XP002049761
MITCHELL W M ET AL: "Induction of mucosal anti-HIV antibodies by facilitated transfection of airway epithelium with lipospermine/DNA complexes", IMMUNOTECHNOLOGY, vol. 1, no. 3, December 1995 (1995-12-01), AMSTERDAM NL, pages 211-219, XP004052723
Download PDF: